DEF 14A: IDEAYA Biosciences Sets Date for 2024 Annual Stockholders Meeting
Proxy Statement
IDEAYA Biosciences will hold its 2024 Annual Meeting of Stockholders online on May 31, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.
Summary
- IDEAYA Biosciences will hold its 2024 Annual Meeting of Stockholders on May 31, 2024, online.
- Stockholders as of the record date of April 4, 2024, are eligible to vote.
- The meeting will address the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, an advisory vote on executive compensation, and a vote on the frequency of future advisory votes on executive compensation.
- The Board of Directors recommends voting for the director nominees, for the ratification of PricewaterhouseCoopers LLP, for the advisory vote to approve executive compensation, and for a one-year frequency for future advisory votes on executive compensation.
- The proxy materials, including the Notice of Annual Meeting and Proxy Statement, were first mailed to stockholders on or about April 19, 2024.
- The company's outstanding voting securities as of the record date consisted of 74,764,628 shares of common stock.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company highlights its progress and achievements, contributing to a slightly positive sentiment.
Positives
- The Annual Meeting will be held online to provide expanded stockholder access and participation.
- The Board recommends a vote 'FOR' the election of director nominees.
- The Board recommends a vote 'FOR' the ratification of PricewaterhouseCoopers LLP.
- The Board recommends a vote 'FOR' the advisory vote to approve executive compensation.
- The Board recommends a vote of '1 YEAR' for the non-binding advisory vote regarding the frequency of future advisory votes by the stockholders on the compensation of our named executive officers.
Future Outlook
The Board plans to continue monitoring developments and may modify its policy on the frequency of future Say-on-Pay advisory votes based on the outcome of Proposal No. 4.
Industry Context
This is a standard proxy statement for a publicly traded biopharmaceutical company, covering routine governance matters such as director elections, auditor ratification, and executive compensation.
Comparison to Industry Standards
- The peer group used for executive compensation benchmarking includes companies like ALX Oncology Holdings, Kura Oncology, and Mersana Therapeutics, which are all pre-commercial biopharma companies.
- The criteria for selecting the peer group included sector, stage of clinical development, headcount, geography, and market capitalization, aligning with common practices in the biopharmaceutical industry.
- The company's executive compensation program, consisting of base salary, annual performance-based bonus, and long-term equity-based incentives, is typical for companies in this sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Program Amendment | Increased the number of options that will be automatically granted each non-employee director upon their initial appointment or election to our Board and on the date of each annual meeting of stockholders thereafter under the Director Compensation Program. | June 6, 2023 | Increased equity compensation for non-employee directors. |
| Director Compensation Program Amendment | Increased the annual cash retainer for each committee member and committee chair. | January 1, 2024 | Increased cash compensation for committee members and chairs. |
| Policy Adoption | Adopted Policy for Recovery of Erroneously Awarded Compensation. | November 2023 | Allows the company to recover cash or equity compensation from executive officers in the event of an accounting restatement. |
Stakeholder Impact
- Shareholders will have the opportunity to vote on key governance matters.
- Executive officers' compensation is subject to shareholder advisory vote.
- The outcome of the votes will influence the company's governance practices and executive compensation decisions.
Next Steps
- Stockholders are encouraged to vote on the proposals outlined in the Proxy Statement.
- The results of the voting will be announced via a Current Report on Form 8-K within four business days after the Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| January 1, 2023 | Retroactive date for annual merit increases to executive base salaries. |
| February 2023 | Board determined to award stock options to Mr. Hata and our Compensation Committee determined to award stock options to our other named executive officers. |
| February 24, 2023 | Grant date of stock options to named executive officers. |
| June 6, 2023 | The Board of Directors increased the number of options that will be automatically granted each non-employee director. |
| June 29, 2023 | Grant date of stock options to Mr. Briseno in connection with his promotion to Senior Vice President, Head of Finance and Investor Relations. |
| July 1, 2023 | Effective date of Mr. Briseno's promotion to Senior Vice President, Head of Finance and Investor Relations. |
| December 7, 2023 | Board of Directors amended the Director Compensation Program to increase the annual cash retainer for each committee member and committee chair. |
| December 20, 2024 | Deadline for stockholder proposals to be considered for inclusion in next year's proxy materials. |
| January 31, 2025 | Start date for stockholders to present a proposal for next year's annual meeting. |
| March 2, 2025 | End date for stockholders to present a proposal for next year's annual meeting. |
| April 1, 2025 | Deadline for stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees to provide notice. |
| May 31, 2024 | Date of the 2024 Annual Meeting of Stockholders. |
Keywords
Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, PricewaterhouseCoopers, Voting, IDEAYA Biosciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.